Full Text
Cost-Utility Analysis (CUA) of Belimumab (BEL) in the Treatment of Adult Patients with Active, Autoantibody-Positive Systemic Lupus Erythematosus (SLE)

Abstract

Authors

J. Walczak J. Kopel E. Sołtys D. Dziurda

Back to Volume 16, Issue 7
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×